FIBP, or Fibroblast Growth Factor (FGF) Interacting Protein, plays a pivotal role in mediating the cellular actions of fibroblast growth factors, which are key to processes such as cell growth, differentiation, and repair. FIBP functions primarily by binding to acidic fibroblast growth factor (aFGF), potentially regulating its availability and activity, thus influencing FGF signaling pathways that are critical for developmental processes and tissue maintenance. The interaction between FIBP and FGFs facilitates the precise modulation of growth factor signaling, ensuring that cellular responses are appropriately coordinated in response to physiological demands. As such, FIBP is integral to maintaining cellular homeostasis and responding effectively to changes in the cellular environment.
The inhibition of FIBP can significantly impact FGF signaling pathways, leading to altered cellular responses and potentially contributing to developmental abnormalities or disease processes. One mechanism of FIBP inhibition involves the disruption of its interaction with FGFs. This disruption could be mediated by competitive binding by other molecules that mimic the structural interface of FIBP or aFGF, effectively blocking their interaction. Another potential mechanism for inhibiting FIBP involves transcriptional regulation. The expression of the FIBP gene could be downregulated through the action of transcriptional repressors or via epigenetic modifications that reduce the accessibility of the FIBP gene to the transcriptional machinery. Additionally, post-translational modifications such as phosphorylation, ubiquitination, or sumoylation might alter the structure or stability of FIBP, affecting its ability to bind to FGFs or its overall functionality. These changes can lead to a decreased capability of FIBP to participate in FGF signaling, which could have broad implications for cell growth and repair processes, particularly in contexts where FGF signaling is crucial for normal development and tissue maintenance. Understanding the mechanisms of FIBP inhibition provides insights into the regulation of growth factor signaling and its implications for health and disease.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PD173074 | 219580-11-7 | sc-202610 sc-202610A sc-202610B | 1 mg 5 mg 50 mg | $47.00 $143.00 $680.00 | 16 | |
PD173074 is a selective FGFR1 inhibitor that can disrupt the FGF signaling pathway, potentially influencing FIBP's function. | ||||||
BGJ398 | 872511-34-7 | sc-364430 sc-364430A sc-364430B sc-364430C | 5 mg 10 mg 50 mg 100 mg | $216.00 $252.00 $594.00 $1009.00 | 4 | |
BGJ398 inhibits FGFR kinase, which may impact FGF signaling and consequently FIBP's interaction with FGFR1. | ||||||
AZD4547 | 1035270-39-3 | sc-364421 sc-364421A | 5 mg 10 mg | $198.00 $309.00 | 6 | |
AZD4547 is another FGFR kinase inhibitor. Its action on the FGF pathway may indirectly affect FIBP's role. | ||||||
SU 5402 | 215543-92-3 | sc-204308 sc-204308A | 1 mg 5 mg | $63.00 $98.00 | 36 | |
SU5402 is an FGFR1 inhibitor that can block FGF signaling, which can indirectly suppress FIBP's function. | ||||||
Erdafitinib | 1346242-81-6 | sc-507388 | 10 mg | $138.00 | ||
Erdafitinib is another FGFR kinase inhibitor, which can disrupt the FGF pathway, subsequently affecting FIBP's role. | ||||||
Lenvatinib | 417716-92-8 | sc-488530 sc-488530A sc-488530B | 5 mg 25 mg 100 mg | $182.00 $661.00 $1690.00 | 3 | |
Lenvatinib, primarily a multi-kinase inhibitor, also targets FGFRs. This action can indirectly suppress FIBP's function in the FGF pathway. | ||||||
Debio-1347 | 1265229-25-1 | sc-507386 | 10 mg | $324.00 | ||
Debio-1347 inhibits FGFRs, which can impact the FGF signaling and potentially the role of FIBP. | ||||||
Dovitinib, Free Base | 405169-16-6 | sc-396771 sc-396771A | 10 mg 25 mg | $170.00 $350.00 | ||
Dovitinib, as a multi-targeted RTK inhibitor, can inhibit FGFRs, potentially affecting FIBP's function in the pathway. | ||||||
BIBF1120 | 656247-17-5 | sc-364433 sc-364433A | 5 mg 10 mg | $184.00 $321.00 | 2 | |
Nintedanib, though a multi-kinase inhibitor, also targets FGFRs, which can disrupt FGF signaling and FIBP's role. | ||||||